Charles A. Deignan
2016
In 2016, Charles A. Deignan earned a total compensation of $1.2M as Chief Financial Officer at Clearside Biomedical, a 150% increase compared to previous year.
Compensation breakdown
| Bonus | $30,000 |
|---|---|
| Non-Equity Incentive Plan | $93,505 |
| Option Awards | $860,139 |
| Salary | $257,500 |
| Total | $1,241,144 |
Deignan received $860.1K in option awards, accounting for 69% of the total pay in 2016.
Deignan also received $30K in bonus, $93.5K in non-equity incentive plan and $257.5K in salary.
Rankings
In 2016, Charles A. Deignan's compensation ranked 7,222nd out of 14,075 executives tracked by ExecPay. In other words, Deignan earned more than 48.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,222 out of 14,075 | 49th |
Division Manufacturing | 2,721 out of 5,489 | 50th |
Major group Chemicals And Allied Products | 891 out of 1,895 | 53rd |
Industry group Drugs | 691 out of 1,538 | 55th |
Industry Pharmaceutical Preparations | 550 out of 1,176 | 53rd |
Source: SEC filing on April 28, 2017.
Deignan's colleagues
We found two more compensation records of executives who worked with Charles A. Deignan at Clearside Biomedical in 2016.
News
Clearside Biomedical CEO George Lasezkay's 2023 pay stays at $1.5M
April 26, 2024
Clearside Biomedical CEO George Lasezkay's 2022 pay falls 35% to $1.5M
April 28, 2023
Clearside Biomedical President and Chief Executive Office George Lasezkay's 2021 pay jumps 71% to $2.3M
April 29, 2022
Clearside Biomedical Chief Commercial Officer Brion Raymond receives $954K in 2018
April 26, 2019